期刊文献+

A抗原表位模拟多肽融合表达载体的构建及鉴定 被引量:2

Peptide mimic of blood group A antigen:construction of the expression vector and determination of the mimicking ability
原文传递
导出
摘要 目的:构建血型A抗原模拟多肽融合表达载体,初步鉴定融合表达蛋白结合抗A抗体的能力。方法:PCR扩增血型A抗原模拟多肽(P17)和谷胱苷肽S-转移酶(GST)编码基因,并连接成P17-GST。双酶切后克隆入原核表达质粒pET28b,酶切、测序鉴定。以BL21(DE3)为表达菌,在IPTG诱导下表达P17-GST融合蛋白,Ni-NTA柱纯化蛋白。红细胞凝集抑制实验分析融合蛋白模拟血型A抗原的能力。结果:成功构建P17基因和GST基因融合的原核表达质粒pET28b-P17-GST,目的基因可以高效表达,纯化的融合蛋白以浓度依赖的方式抑制A型红细胞的凝集作用。结论:血型A抗原的模拟多肽序列与GST的融合表达蛋白可特异性结合抗A抗体,具有替代血型A多糖抗原潜能,为发展新型的抗A抗体滤除材料提供了依据。 Objective:To construction the blood group A mimitope and GST fusion protein expression vector and determine the mimic ability of the fusion protein.Method:The P17 and GST genes were amplified by PCR and ligated as P17-GST gene. The P17-GST gene was cloned into pET28b plasmid and named pET28b-P17-GST. Restrict digest and sequencing were used to identify the correct pET28b-P17-GST plasmid. Then the pET28b-P17-GST was transformed into E.coli BL21 (DE3), P17-GST fusion protein was induced by IPTG and purified by Ni-NTA resin. The inhibit agglutination assay was used to determine the group A-mimic ability of the fusion protein.Result:The pET28b-P17-GST vector was constructed successfully and could express the fusion protein efficiently. The purified fusion protein could inhibit the group A red blood cell agglutination induced by anti-A antibody in a dose dependent manner.Conclusion:The P17-GST fusion protein can mimic the blood group A antigen and has the potential to instead of natural blood group A antigen.
出处 《临床血液学杂志(输血与检验)》 CAS 2007年第6期247-250,共4页 Journal of Clinical Hematology(Blood Transfusion & Laboratory Medicine)
关键词 血型A抗原 模拟多肽 融合蛋白 Blood group A antigen Peptide mimic Fusion protein
  • 相关文献

参考文献8

  • 1TYDEN G,DONAUER J,WADSTROMJ,et al.I mplementation of a Protocol for ABO-incompatible kidney transplantation-a three-center experience with60consecutive transplantations. Transplantation . 2007
  • 2NORDEN G,BRIGGS D,COCKWELL P,et al.ABO-incompatible live donor renal transplantation u-sing blood group A/B carbohydrate antigen i mmuno-adsorption and anti-CD20antibody treat ment. Xe-notransplantation . 2006
  • 3TYDEN G,KUMLIEN G,GENBERG H,et al.ABO incompatible kidney transplantations withoutsplenectomy,using antigen-specific i mmunoadsorp-tion and rituxi mab. AmJ Transplant . 2005
  • 4BARENHOLZ A,HOVAV A-H,FISHMAN Y,et al.A peptide mi metic of the mycobacterial mannosy-lated lipoarabinomannan:characterization and poten-tial applications. Journal of Medical Microbiology . 2007
  • 5GEVORKIAN G,SEGURA E,ACERO G,et al.Peptide mi motopes of Mycobacterium tuberculosis carbohydrate i mmunodeterminants. Biochemical Journal . 2005
  • 6SHARMA A,SAHA A,BHATTACHARJEE S,et al.Specific and randomly derived i mmunoactive pep-tide mi motopes of mycobacterial antigens. Clin Vaccine I mmunol . 2006
  • 7Gunilla Kumlien , Lisbeth Ullstr&ouml,m , Anita Losvall , Lars-Gunnar Persson , and Gunnar Tyd&eacute,n.Clinical experience with a new apheresis filter that specifically depletes ABO blood group antibodies. Transfusion . 2006
  • 8Lang J,Zhan JB,Xu LH,Yan ZK.Identification of peptide mimetics of xenoreactive a-Gal antigenic epitope by phage display. Biochem Biophy Res Co . 2006

同被引文献13

  • 1李强,高天文,焦彬,于晓云,胡雪慧,卢涛,栾琪,刘玲,刘玉峰.蛋白质组学技术鉴定白癜风相关的黑素细胞膜抗原[J].中华皮肤科杂志,2007,40(1):48-50. 被引量:1
  • 2Barenholz A,Hovav AH,Fishman Y,et al.A peptide mimetic of the mycobacterial mannosylated lipoarabinomannan:characterization and potential applications.J Med Microbiol,2007,56(Pt 5):579-586.
  • 3Wagner S,Hafner C,Allwardt D,et al.Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro.J Immunol,2005,174(2):976-982.
  • 4Braun SE,Chen K,Foster RG,et al.The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells.J Immunol,2000,164(8):4025-4031.
  • 5Ott TR,Lio FM,Olshefski D,et al.Determinants of high-affinity binding and receptor activation in the N-terminus of CCL-19 (MIP-3 beta).Biochemistry,2004,43(12):3670-3678.
  • 6Jilaveanu LB,Aziz SA,Kluger HM.Chemotherapy and biologic therapies for melanoma:do they work?.Clin Dermatol,2009,27(6):614-625.
  • 7Montgomery PA,Locke JE,King KE,et al.ABO incompatible renal transplantation:a paradigm ready for broad implementation.Transplantation,2009,87(8):1246-1255.
  • 8Rangel-Moreno J,Moyron-Quiroz J,Kusser K,et al.Role of CXC chemokine ligand 13,CC chemokine ligand (CCL) 19,and CCL21 in the organization and function of nasal-associated lymphoid tissue.J Immunol,2005,175(8):4904-4913.
  • 9Jilaveanu LB,Aziz SA,Kluger HM.Chemotherapy and biologic therapies for melanoma:do they work? Clin Dermatol,2009,27(6):614-625.
  • 10Montgomery RA,Locke JE,King KE,et al.ABO incompatible renal transplantation:a paradigm ready for broad implementation.Transplantation,2009,87(8):1246-1255.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部